Market revenue in 2023 | USD 512.7 million |
Market revenue in 2030 | USD 954.7 million |
Growth rate | 9.3% (CAGR from 2023 to 2030) |
Largest segment | Glucose testing |
Fastest growing segment | Glucose testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Glucose testing, A1C testing, Direct LDL testing, Lipid panel testing, Prostate-specific antigen testing, COVID-19 testing, BUN testing, Vitamin D testing, Thyroid-stimulating hormone testing, Serum Nicotine / Cotinine testing, High sensitivity CRP testing, Testosterone testing, ALT testing, Cortisol testing, Creatinine testing, AST testing, Other blood tests |
Key market players worldwide | Abbott Laboratories, Roche Holding AG ADR, Bio-Rad Laboratories Inc, BioMerieux SA, Quest Diagnostics Inc, Biomerica Inc, Becton Dickinson & Co, Siemens Healthineers AG ADR, Danaher Corp, Trinity Biotech PLC ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood testing market will help companies and investors design strategic landscapes.
Glucose testing was the largest segment with a revenue share of 14.47% in 2023. Horizon Databook has segmented the Indonesia blood testing market based on glucose testing, a1c testing, direct ldl testing, lipid panel testing, prostate-specific antigen testing, covid-19 testing, bun testing, vitamin d testing, thyroid-stimulating hormone testing, serum nicotine / cotinine testing, high sensitivity crp testing, testosterone testing, alt testing, cortisol testing, creatinine testing, ast testing, other blood tests covering the revenue growth of each sub-segment from 2018 to 2030.
Rising prevalence of chronic diseases coupled with rising disposable income are key factors boosting the demand for blood-based diagnostic tests in the nation. According to data from the George Institute for Global Health’s research on “Reducing the burden of CVD in Indonesia,” an estimated 37% of deaths in Indonesia occur due to cardiovascular diseases.
Some of the major risk factors for CVD in the nation are high cholesterol, diabetes, obesity, high blood pressure, and tobacco. Data from WHO also indicates that non-communicable diseases account for 37% of all deaths in the nation. Alcohol abuse, tobacco usage, lack of physical activity, and obesity are major causes of non-communicable diseases.
Horizon Databook provides a detailed overview of country-level data and insights on the Indonesia blood testing market , including forecasts for subscribers. This country databook contains high-level insights into Indonesia blood testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account